Grant opportunity preview
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Offered by National Institutes of Health
EducationNationalJanuary 7, 2027
Opportunity summary
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer…
Sign in to review full eligibility requirements, application details, matching insights, and verified source links.